Effects of pharmacologic therapy on health-related quality of life in elderly patients with atrial fibrillation: A systematic review of randomized and nonrandomized trials

Clinical Medicine Insights: Cardiology

Volumn 7, Issue , 2013, Pages 1-20

  Pepine, Carl J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Aged; Antiarrhythmic agents; Arrhythmia; Atrial fibrillation; Health related quality of life

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGITALIS; PLACEBO; PROPAFENONE; SOTALOL;

ANXIETY; CARDIOVERSION; DEPRESSION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; EXERCISE; HEART ATRIUM FIBRILLATION; HEART RATE; HEART RHYTHM; HUMAN; PAROXYSMAL HEART ATRIUM FIBRILLATION; PHARMACEUTICAL CARE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHORT FORM 36; SINUS RHYTHM; SYMPTOM; SYSTEMATIC REVIEW;

EID: 84873124863     PISSN: 11795468     EISSN: None     Source Type: Journal    
DOI: 10.4137/CMC.S10628     Document Type: Review

References (76)

1. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation a report of the American college of cardiology foundation/American heart association task force on practice guidelines developed in partnership with the European society of cardiology and in collaboration with the European heart rhythm association and the heart rhythm society. J Am Coll Cardiol. 2011;57(11):e101-98.
2. Coyne KS, Paramore C, Grandy S, et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006;9(5):348-56.
3. Berry C, Rae A, Taylor J, Brady AJ. Atrial fibrillation in the elderly. Br J Cardiology. 2003;10(5):373-8.
4. Rich MW. Epidemiology of atrial fibrillation. J Interv Card Electrophysiol. 2009;25(1):3-8.
5. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982;306(17):1018-22.
6. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-5.
7. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994;74(3):236-41.
8. Valderrama AL, Dunbar SB, Mensah GA. Atrial fibrillation: public health implications. Am J Prev Med. 2005;29(5 Suppl 1):75-80.
9. Bajpai A, Savelieva I, Camm AJ. Epidemiology and economic burden of atrial fibrillation. Touch Briefings. 2007;14-17.
10. Lip GY, Tse HF. Management of atrial fibrillation. Lancet. 2007;370(9587): 604-18.
11. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104(11):1534-9.
12. Fang MC, Chen J, Rich MW. Atrial fibrillation in the elderly. Am J Med. 2007;120(6):481-7.
13. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-8.
14. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation. 2003;108(6):711-6.
15. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946-52.
16. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96(7):2455-61.
17. Wozakowska-Kaplon B, Opolski G, Kosior D, et al. Cognitive disorders in elderly patients with permanent atrial fibrillation. Kardiol Pol. 2009;67(5):487-93.
18. Puccio D, Novo G, Baiamonte V, et al. Atrial fibrillation and mild cognitive impairment: what correlation? Minerva Cardioangiol. 2009;57(2):143-50.
19. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987;147(9):1561-4.
20. Fuster V, Mearns BM. Global collaboration needed for AF. Nat Rev Cardiol. 2010;7(3):115-6.
21. Dorian P, Jung W, Newman D, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol. 2000;36(4):1303-9.
22. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-83.
23. Friberg J, Buch P, Scharling H, et al. Rising rates of hospital admissions for atrial fibrillation. Epidemiology. 2003;14(6):666-72.
24. Dorian P, Guerra PG, Kerr CR, et al. Validation of a new simple scale to measure symptoms in atrial fibrillation: The Canadian Cardiovascular Society Severity in Atrial Fibrillation Scale. Circ Arrhythmia Electrophysiol. 2009;2:218-24.
25. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med. 2006;119(5):448-419.
26. Lane DA, Langman CM, Lip GY, Nouwen A. Illness perceptions, affective response, and health-related quality of life in patients with atrial fibrillation. J Psychosom Res. 2009;66(3):203-10.
27. Wei TM, Wang L. Anxiety symptoms in patients with hypertension: a community-based study. Int J Psychiatry Med. 2006;36(3):315-22.
28. Jenkins LS, Brodsky M, Schron E, et al. Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005;149(1):112-20.
29. Ferrans CE, Powers MJ. Psychometric assessment of the Quality of Life Index. Res Nurs Health. 1992;15(1):29-38.
30. Yamashita T, Kumagai K, Koretsune Y, et al. A new method for evaluating quality of life specific to patients with atrial fibrillation: atrial fibrillation quality of life questionnaire (AFQLQ). Jpn J Electrocardiol. 2003;23:332-43. In Japanese.
31. Yamashita T, Komatsu M, Kumagai K, et al. Internal consistency and reproducibility of atrial fibrillation Quality of Life Questionnaire (AFQLQ). Jpn J Electrocardiol. 2005;25:488-94. In Japanese.
32. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-71.
33. Beck AT, Beck RW. Screening depressed patients in family practice. A rapid technic. Postgrad Med. 1972;52(6):81-5.
34. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Phychol Health. 1999;14:1-24.
35. Nelson E, Wasson J, Kirk J, et al. Assessment of function in routine clinical practice: description of the COOP Chart method and preliminary findings. J Chronic Dis. 1987;40 Suppl 1:55S-69S.
36. Beaufait DW, Nelson EC, Landgraf JM, et al. COOP measures of functional status. In: Stewart MA, Tudiver F, Bass MJ, et al, editors. Tools for Primary Care Research, Research Methods for Primary Care, Volume 2. Thousand Oaks, CA: Sage Publications, Inc; 1992:151-67.
37. Hlatky MA, Boineau RE, Higginbotham MB, et al. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol. 1989;64(10):651-4.
38. Parkerson GR Jr, Broadhead WE, Tse CK. The Duke Health Profile. A 17-item measure of health and dysfunction. Med Care. 1990;28(11):1056-72.
39. Weinman J, Petrie KJ, Moss-Morris R, Horne R. The illness perception questionnaire: a new method for assessing the cognitive representation of illness. Psychol Health. 1996;11:43105-114.
40. Rector RS, Kubo SH, Cohn JN. Patients' self-assessment of their congestive heart failure, II: content, reliability, and validity of a new measure. Heart Fail. 1987;3:198-209.
41. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24(4):385-96.
42. Goldman L, Hashimoto B, Cook EF, Loscalzo A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation. 1981;64(6):1227-34.
43. Ware JE Jr, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, MA: Health Assessment Lab, New England Medical Center; 1994.
44. Ware JE Jr, Kosinski M, Bayliss MS, et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care. 1995;33(Suppl 4):AS264-79.
45. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220-33.
46. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the State-trait Anxiety Inventory. Mountain View, CA: Consulting Psychologists Press; 1983.
47. Dipietro L, Caspersen CJ, Ostfeld AM, Nadel ER. A survey for assessing physical activity among older adults. Med Sci Sports Exerc. 1993; 25(5):628-42.
48. Perret Guillaume C, Briancon S, Wahl D, et al. Quality of life in elderly inpatients with atrial fibrillation as compared with controlled subjects. J Nutr Health Aging. 2010;14(2):161-6.
49. Howes CJ, Reid MC, Brandt C, et al. Exercise tolerance and quality of life in elderly patients with chronic atrial fibrillation. J Cardiovasc Pharmacol Ther. 2001;6(1):23-9.
50. Kang Y, Bahler R. Health-related quality of life in patients newly diagnosed with atrial fibrillation. Eur J Cardiovasc Nurs. 2004;3(1):71-6.
51. Paquette M, Roy D, Talajic M, et al. Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. Am J Cardiol. 2000;86(7):764-8.
52. Reynolds MR, Lavelle T, Essebag V, et al. Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. Am Heart J. 2006;152(6):1097-103.
53. Ogawa S, Yamashita T, Yamazaki T, et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J. 2009;73(2):242-8.
54. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41(10):1690-6.
55. Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study. Am Heart J. 2002;143(6):991-1001.
56. Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. 2004;43(2):241-7.
57. Shelton RJ, Clark AL, Goode K, et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart. 2009;95(11):924-30.
58. Dorian P, Paquette M, Newman D, et al. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J. 2002; 143(6):984-90.
59. Singh SN, Tang XC, Singh BN, et al. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy. J Am Coll Cardiol. 2006;48(4):721-30.
60. Tsuneda T, Yamashita T, Fukunami M, et al. Rate control and quality of life in patients with permanent atrial fibrillation: the Quality of Life and Atrial Fibrillation (QOLAF) Study. Circ J. 2006;70(8):965-70.
61. Thrall G, Lip GY, Carroll D, Lane D. Depression, anxiety, and quality of life in patients with atrial fibrillation. Chest. 2007;132(4):1259-64.
62. Healey JS, Parkash R, Pollak T, et al. Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: etiology and initial investigations. Can J Cardiol. 2011;27(1):31-7.
63. Groenveld HF, Crijns HJ, Van Den Berg MP, et al. Quality in life in lenient versus strict rate control in patients with permanent atrial fibrillation, data from RACE II [abstract SP14]. Heart Rhythm Society 31st Annual Scientific Sessions, May 12-15, 2010, Denver, CO.
64. Van Gelder I, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363-73.
65. Camm AJ. Differences in clinical outcomes with rhythm and rate control therapies for atrial fibrillation in the recordAF registry [oral presentation]. American Heart Association Scientific Sessions, Nov 14-18, 2009, Orlando, FL.
66. Camm AJ, Breithardt G, Crijns H, et al. Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation: RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). J Am Coll Cardiol. 2011;58(5):493-501.
67. Reiffel JA, Kowey PR, Myerburg R, et al. Practice patterns among United States cardiologists for managing adults with atrial fibrillation (from the AFFECTS Registry). Am J Cardiol. 2010;105(8):1122-9.
68. Le Heuzey JY, Breithardt G, Camm J, et al. The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. Am J Cardiol. 2010;105(5):687-93.
69. Multaq [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2012.
70. FDA Drug Safety Communication: Severe liver injury associated with the use of dronedarone (marketed as Multaq). Available at: http://www.fda.gov/drugs/drugsafety/ucm240011.htm. Accessed on Jul 13, 2011.
71. Potential signals of serious risks/new safety information identified by the adverse event reporting system (AERS) between Jul-Sep 2010. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm237585.htm. Accessed on Mar 21, 2011.
72. QuarterWatch: 2010 Quarter 1. Monitoring MedWatch Reports. Signals for acetaminophen, dronedarone and botulinum toxin products [executive summary]. Available at: http://freepdfhosting.com/078147c86d.pdf. Accessed on Mar 21, 2011.
73. Merck to Acquire Rights to Vernakalant i.v. in Canada, Mexico and the United States from Astellas. Available at: http://www.merck.com/newsroom/news-release-archive/research-and-development/2011_0726.html. Accessed on Nov 1, 2011.
74. Camm AJ, Capucci A, Hohnloser SH, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011;57(3):313-21.
75. Spertus J, Dorian P, Bubien R, et al. Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2011;4(1):15-25.
76. van Gelder I, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834-40.